High serum 25(OH)D linked to lower breast cancer mortality

High serum 25(OH)D linked to lower breast cancer mortality

(HealthDay)—Higher concentrations of serum 25-hydroxyvitamin D (25[OH]D) are associated with lower mortality from breast cancer, according to a meta-analysis published in the March issue of Anticancer Research.

Sharif B. Mohr, M.P.H., from the Naval Health Research Center in San Diego, and colleagues conducted a meta-analysis of five studies to examine the correlation between 25(OH)D at diagnosis and mortality from breast cancer. A random-effects model was used to calculate hazard ratios.

The researchers observed a correlation between higher 25(OH)D concentration and lower case-fatality rates after breast cancer diagnosis. Compared with patients in the lowest quintile of 25(OH)D, those in the highest quintile had about half the death rate from breast cancer (hazard ratio, 0.56).

"High serum 25(OH)D was associated with lower from breast cancer. Serum 25(OH)D in all patients with should be restored to the normal range (30 to 80 ng/mL), with appropriate monitoring," the authors write. "Clinical or field studies should be initiated to confirm that this association was not due to reverse causation."

More information: Abstract
Full Text

add to favorites email to friend print save as pdf

Related Stories

Vitamin D increases breast cancer patient survival

Mar 06, 2014

Breast cancer patients with high levels of vitamin D in their blood are twice as likely to survive the disease as women with low levels of this nutrient, report University of California, San Diego School of Medicine researchers ...

CDC: breast cancer mortality higher in black women

Nov 15, 2012

(HealthDay)—With earlier detection and better treatment, the mortality rate from breast cancer has fallen over the last two decades; black women, however, still die from the disease at a disproportionately ...

Recommended for you

XenOPAT, mouse models for personalized cancer treatment

13 hours ago

On September 8th, the company XenOPAT SL, a spin-off of the Institute of Biomedical Research (IDIBELL) and the Catalan Institute of Oncology (ICO) was established with the aim of bringing the company the latest scientific ...

User comments